Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Boehringer Ingelheim
Dow
Colorcon
Merck

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for D-Tryptophan


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug D-Tryptophan?

D-Tryptophan is an investigational drug.

There have been 18 clinical trials for D-Tryptophan. The most recent clinical trial was a Phase 2 trial, which was initiated on December 9th 2020.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Adenocarcinoma, and Breast Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), NewLink Genetics Corporation, and Southwest Oncology Group.

There is one US patent protecting this investigational drug and eight international patents.

Recent Clinical Trials for D-Tryptophan
TitleSponsorPhase
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk ScoreNational Cancer Institute (NCI)Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk ScoreNRG OncologyPhase 3
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive SurgeryAdvanced Accelerator ApplicationsPhase 1

See all D-Tryptophan clinical trials

Clinical Trial Summary for D-Tryptophan

Top disease conditions for D-Tryptophan
Top clinical trial sponsors for D-Tryptophan

See all D-Tryptophan clinical trials

US Patents for D-Tryptophan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
D-Tryptophan ⤷  Sign up for a Free Trial Generation of cytotoxic tumor specific cell lines and uses thereof Ramot at Tel-Aviv University Ltd. (Tel-Aviv, IL) ⤷  Sign up for a Free Trial
D-Tryptophan ⤷  Sign up for a Free Trial Nuclear targeting sequences Yeda Research and Development Co. Ltd. (Rehovot, IL) ⤷  Sign up for a Free Trial
D-Tryptophan ⤷  Sign up for a Free Trial Use of GPR83 to identify pruritus-related substances University of Miyazaki (Miyazaki, JP) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for D-Tryptophan

Drugname Country Document Number Estimated Expiration Related US Patent
D-Tryptophan European Patent Office EP2950808 2033-02-04 ⤷  Sign up for a Free Trial
D-Tryptophan World Intellectual Property Organization (WIPO) WO2014118785 2033-02-04 ⤷  Sign up for a Free Trial
D-Tryptophan European Patent Office EP2134373 2027-02-28 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Boehringer Ingelheim
Dow
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.